Literature DB >> 25876201

A reader's guide to the bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.

Jacques Grosset1, Andrew Vernon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25876201      PMCID： PMC5884099          DOI： 10.1164/rccm.201502-0367ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  17 in total

1.  Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals.

Authors:  Sarah Schmidt Grant; Benjamin B Kaufmann; Nikhilesh S Chand; Nathan Haseley; Deborah T Hung
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

2.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Authors:  Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

Review 3.  Dormancy of Mycobacterium tuberculosis and latency of disease.

Authors:  L G Wayne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

4.  Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.

Authors:  Sandeep Tyagi; Nicole C Ammerman; Si-Yang Li; John Adamson; Paul J Converse; Rosemary V Swanson; Deepak V Almeida; Jacques H Grosset
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-05       Impact factor: 11.205

5.  Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Authors:  A H Diacon; P R Donald; A Pym; M Grobusch; R F Patientia; R Mahanyele; N Bantubani; R Narasimooloo; T De Marez; R van Heeswijk; N Lounis; P Meyvisch; K Andries; D F McNeeley
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

6.  14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.

Authors:  Andreas H Diacon; Rodney Dawson; Florian von Groote-Bidlingmaier; Gregory Symons; Amour Venter; Peter R Donald; Christo van Niekerk; Daniel Everitt; Helen Winter; Piet Becker; Carl M Mendel; Melvin K Spigelman
Journal:  Lancet       Date:  2012-07-23       Impact factor: 79.321

7.  Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species.

Authors:  Takahiro Yano; Sacha Kassovska-Bratinova; J Shin Teh; Jeffrey Winkler; Kevin Sullivan; Andre Isaacs; Norman M Schechter; Harvey Rubin
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

8.  Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

Authors:  Murad Ibrahim; Chantal Truffot-Pernot; Koen Andries; Vincent Jarlier; Nicolas Veziris
Journal:  Am J Respir Crit Care Med       Date:  2009-07-09       Impact factor: 21.405

9.  Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis.

Authors:  Andreas H Diacon; Rodney Dawson; Florian Von Groote-Bidlingmaier; Gregory Symons; Amour Venter; Peter R Donald; Almari Conradie; Ngozi Erondu; Ann M Ginsberg; Erica Egizi; Helen Winter; Piet Becker; Carl M Mendel
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.

Authors:  Nicolas Veziris; Murad Ibrahim; Nacer Lounis; Koen Andries; Vincent Jarlier
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240
View more
  3 in total

Review 1.  Update in Mycobacterium tuberculosis lung disease 2014.

Authors:  Paul Elkington; Alimuddin Zumla
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

Review 2.  Update in Tuberculosis/Pulmonary Infections 2015.

Authors:  Serena P Koenig; Jennifer Furin
Journal:  Am J Respir Crit Care Med       Date:  2016-07-15       Impact factor: 21.405

3.  Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).

Authors:  Andréanne Lupien; Anthony Vocat; Caroline Shi-Yan Foo; Emilyne Blattes; Jean-Yves Gillon; Vadim Makarov; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.